November 1, 2017 05:00 AM EDT
Financing

Fra­zier boosts next pure-play biotech fund to $419M, read­ies new bets for a prac­ticed strat­e­gy

John Carroll

Editor & Founder

Jamie Top­per Fra­zier Health­care Part­ners

The mon­ey in biotech keeps get­ting big­ger.

Af­ter Fra­zier Health­care Part­ners closed its first ded­i­cat­ed biotech fund with $262 mil­lion al­most ex­act­ly two years ago, man­ag­ing gen­er­al part­ner Jamie Top­per and his crew of VC spe­cial­ists went af­ter some 16 to 18 new biotech in­vest­ments, hew­ing to the start­up rounds that are their sweet spot — and which ac­counts for the bulk of the cash.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is ready to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

Fed­er­al judge grants pause to Pfiz­er, BioN­Tech in Covid-19 patent law­suit tri­al brought by Mod­er­na

Astel­las writes down an­oth­er piece of its Au­dentes gene ther­a­py ac­qui­si­tion

New FDA tri­al in­no­va­tion cen­ter launch­es with demon­stra­tion to in­crease in­dus­try in­ter­ac­tions

A service from the Financial Times